NASDAQ:PRAN - Prana Biotechnology Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.56 -0.07 (-4.29 %) (As of 05/21/2019 05:12 AM ET)Previous Close$1.63Today's Range$1.56 - $1.601052-Week Range$1.09 - $2.91Volume13,220 shsAverage Volume130,956 shsMarket Capitalization$13.88 millionP/E RatioN/ADividend YieldN/ABeta1.05 ProfileAnalyst RatingsChartFinancialsHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Prana Biotechnology Limited researches and develops therapeutic drugs for the treatment of Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidates include PBT434 that is in Phase I clinical trial for the treatment for Parkinson's disease and other movement disorders; and PBT2, which has completed four Phase I studies and a Phase IIa clinical trial for patients with Alzheimer's disease. It also completed the IMAGINE Phase II biomarker imaging trial in Alzheimer's disease; and a open label IMAGINE Extension study and the Reach2HD Phase IIa trial in Huntington disease. The company was founded in 1997 and is based in Melbourne, Australia. Receive PRAN News and Ratings via Email Sign-up to receive the latest news and ratings for PRAN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PRAN Previous Symbol CUSIPN/A CIK1131343 Webwww.pranabio.com Phone61-3-9349-4906Debt Debt-to-Equity RatioN/A Current Ratio4.37 Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$150,000.00 Price / Sales92.56 Cash FlowN/A Price / Cash FlowN/A Book Value$1.40 per share Price / Book1.11Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees14 Outstanding Shares8,900,000Market Cap$13.88 million Next Earnings DateN/A OptionableNot Optionable Prana Biotechnology (NASDAQ:PRAN) Frequently Asked Questions What is Prana Biotechnology's stock symbol? Prana Biotechnology trades on the NASDAQ under the ticker symbol "PRAN." Has Prana Biotechnology been receiving favorable news coverage? News headlines about PRAN stock have trended somewhat positive recently, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Prana Biotechnology earned a media sentiment score of 1.5 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the next several days. Who are some of Prana Biotechnology's key competitors? Some companies that are related to Prana Biotechnology include Seelos Therapeutics (SEEL), AzurRx BioPharma (AZRX), Oramed Pharmaceuticals (ORMP), Zosano Pharma (ZSAN), Moleculin Biotech (MBRX), AEterna Zentaris (AEZS), Novan (NOVN), Avadel Pharmaceuticals (AVDL), IntelGenx Technologies (IGXT), PLx Pharma (PLXP), Bellerophon Therapeutics (BLPH), CTI BioPharma (CTIC), Teligent (TLGT), Lipocine (LPCN) and Clearside Biomedical (CLSD). What other stocks do shareholders of Prana Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Prana Biotechnology investors own include Novavax (NVAX), Catalyst Pharmaceuticals (CPRX), Madrigal Pharmaceuticals (MDGL), Conatus Pharmaceuticals (CNAT), Intercept Pharmaceuticals (ICPT), Microbot Medical (MBOT), Progenics Pharmaceuticals (PGNX), Arena Pharmaceuticals (ARNA), CTI BioPharma (CTIC) and Geron (GERN). Who are Prana Biotechnology's key executives? Prana Biotechnology's management team includes the folowing people: Mr. Geoffrey Paul Kempler, Co-Founder, Exec. Chairman, CEO & MD (Age 64)Ms. Kathryn Andrews, Chief Financial Officer (Age 52)Dr. David A. Stamler, Chief Medical Officer, Sr. VP of Clinical Devel. and Member of R&D Advisory Board (Age 58)Prof. Rudolph Emile Tanzi, Chief Scientific Advisor and Member of R&D Advisory BoardDr. Steven D. Targum M.D., Chief Medical Advisor How do I buy shares of Prana Biotechnology? Shares of PRAN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Prana Biotechnology's stock price today? One share of PRAN stock can currently be purchased for approximately $1.56. How big of a company is Prana Biotechnology? Prana Biotechnology has a market capitalization of $13.88 million and generates $150,000.00 in revenue each year. The biotechnology company earns $-6,400,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Prana Biotechnology employs 14 workers across the globe. What is Prana Biotechnology's official website? The official website for Prana Biotechnology is http://www.pranabio.com. How can I contact Prana Biotechnology? Prana Biotechnology's mailing address is Level 3 460 Bourke Street, Melbourne C3, 3000. The biotechnology company can be reached via phone at 61-3-9349-4906 or via email at [email protected] MarketBeat Community Rating for Prana Biotechnology (NASDAQ PRAN)Community Ranking: 2.1 out of 5 ( )Outperform Votes: 142 (Vote Outperform)Underperform Votes: 200 (Vote Underperform)Total Votes: 342MarketBeat's community ratings are surveys of what our community members think about Prana Biotechnology and other stocks. Vote "Outperform" if you believe PRAN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRAN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/21/2019 by MarketBeat.com StaffFeatured Article: Technical Analysis Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.